Table 2 Patency outcomes

6-month patency outcomes

Target lesion primary patency (n=39)

28 (71.8)

-

De novo (n=13)

9 (69.2)

1.00

Recurrent (n=26)

19 (73.1)

JAS (n=21)

15 (71.4)

1.00

Non-JAS (n=18)

13 (72.2)

Circuit access primary patency (n=35)

22 (62.9)

-

De novo (n=9)

7 (77.8)

0.43

Recurrent (n=26)

15 (57.7)

Secondary patency (n=36)

35 (97.2)

-

Circuit primary assisted patency (n=35)

33 (94.3)

-

12-month patency outcomes

Target lesion primary patency (n=36)

16 (44.4)

De novo (n=12)

6 (50.0)

0.73

Recurrent (n=24)

10 (41.6)

JAS (n=20)

9 (45.0)

1.00

Non-JAS (n=16)

7 (43.8)

Circuit access primary patency (n=32)

10 (31.3)

-

De novo (n=8)

3 (37.5)

0.25

Recurrent (n=24)

7 (29.2)

Secondary patency (n=34)

32 (94.1)

-

Circuit primary assisted patency (n=32)

28 (87.5)

-

Mean TLR-free duration, months (±sd)

8.6 ± 4.5

-

Mean time to target lesion reintervention, months (±sd)

7.2 ± 3.6

-

De novo

7.1 ± 3.6

0.56

Recurrent

6.4 ± 3.8

JAS

7.4 ± 4.1

1.00

Non-JAS

5.4 ± 2.6

Reasons for reintervention

Dropping access flow

15

High venous pressure

5

Cannulation difficulties

1

Thrombosis

3

Retrograde flow

1